Table 4. Correlation of SHARP1 expression with clinicopathological characteristics in endometrial cancer.
| Total | SHARP1 expression | |||||
| Characteristic | (n = 110) | Strong (%) | Weak (%) | Negative (%) | ?2 | P |
| n = 35 | n = 64 | n = 11 | ||||
| Age | ||||||
| ≤55 | 47 | 18 (38.3%) | 25 (53.2%) | 4 (8.5%) | 1.616 | 0.446 |
| >55 | 63 | 17 (27.0%) | 39 (61.9%) | 7 (11.1%) | ||
| Pathology | ||||||
| Endometrioid | 97 | 35 (36.1%) | 54 (55.7%) | 8 (8.2%) | 8.102 | 0.017 |
| papillary serous | 13 | 0 (0%) | 10 (76.9%) | 3 (23.1%) | ||
| or clear cell | ||||||
| Grade of EEC | ||||||
| G1 | 63 | 25 (39.7%) | 34 (54.0%) | 4 (6.3%) | 19.840 | 0.001 |
| G2 | 29 | 10 (34.5%) | 18 (62.1%) | 1 (3.4%) | ||
| G3 | 5 | 0 (0%) | 2 (40.0%) | 3 (60.0%) | ||
| Myometrial | ||||||
| invasion | ||||||
| ≤1/2 | 78 | 31 (39.7%) | 43 (55.1%) | 4 (5.1%) | 12.087 | 0.002 |
| >1/2 | 32 | 4 (12.5%) | 21 (65.6%) | 7 (21.9%) | ||
| Lymph node | ||||||
| metastasis | ||||||
| Negative | 103 | 35 (34.0%) | 60 (58.3%) | 8 (7.8%) | 10.451 | 0.005 |
| Positive | 7 | 0 (0%) | 4 (57.1%) | 3 (42.9%) | ||
| Blood vessel permeation in the myometrium | ||||||
| Negative | 90 | 32 (35.6%) | 52 (57.8%) | 6 (6.7%) | 7.687 | 0.021 |
| Positive | 20 | 3 (15.0%) | 12 (60.0%) | 5 (25.0%) | ||
| FIGO stage | ||||||
| I or II | 100 | 35 (35.0%) | 57 (57.0%) | 8 (8.0%) | 8.164 | 0.017 |
| III or IV | 10 | 0 (0%) | 7 (70.0%) | 3 (30.0%) | ||
| ER expression | ||||||
| Negative | 19 | 3 (15.8%) | 12 (63.1%) | 4 (21.1%) | 4.758 | 0.093 |
| Positive | 91 | 32 (35.2%) | 52 (57.1%) | 7 (7.7%) | ||
| PR expression | ||||||
| Negative | 18 | 3 (16.7%) | 12 (66.7%) | 3 (16.7%) | 2.776 | 0.250 |
| Positive | 92 | 32 (34.8%) | 52 (56.5%) | 8 (8.7%) | ||
| p53 expression | ||||||
| Negative | 78 | 27 (34.6%) | 46 (59.0%) | 5 (6.4%) | 4.143 | 0.126 |
| Positive | 32 | 8 (25%) | 18 (56.3%) | 6 (18.7%) | ||
ER, estrogen receptor; PR, progesterone receptor.